{"schema_version":"secwatch.filing_event.v1","accession":"0001740797-23-000075","form_type":"8-K","ticker":"AVAI","cik":"0001740797","company_name":"AVAI BIO, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.279050+00:00","generated_at":"2026-06-08T09:49:44.612129+00:00","sec_items":["1.01","3.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avant Technologies appoints Timothy Lantz as CEO; prior CEO Racuis remains CFO","bullets":["Timothy Lantz named Director and CEO effective Nov 3, 2023; replaces Vitalis Racuis who vacates CEO but stays CFO/Treasurer.","Lantz receives $480k annual base salary, 50% annual cash bonus, and quarterly RSA of $375k (15% VWAP discount) plus 3% ISO grant.","Paul Averill resigned as COO effective Nov 3; no disagreement cited; potential consulting agreement under Lantz.","Equity grants to Lantz issued as unregistered securities under Section 4(a)(2); no general solicitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001740797-23-000075","json":"https://secwatch.observer/filing/0001740797-23-000075.json","markdown":"https://secwatch.observer/filing/0001740797-23-000075.md","text":"https://secwatch.observer/filing/0001740797-23-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000075/0001740797-23-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000075/avai_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:49:44.612129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b787a1bca","claim":"Timothy Lantz was appointed as Director and Chief Executive Officer at AVAI BIO, INC..","evidence_excerpt":"On November 3, 2023, Avant Technologies Inc. (the “Company”) and Timothy Lantz entered into an Employment Agreement pursuant to which Mr. Lantz was retained as Director and Chief Executive Officer (“CEO”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000075/0001740797-23-000075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"738658c7ec","claim":"Vitalis Racuis changed role as Chief Financial Officer and Treasurer at AVAI BIO, INC..","evidence_excerpt":"Vitalis Racuis – Vacate CEO position Effective November 3, 2023 with the appointment of Mr. Lantz as Director and CEO, Mr. Racuis vacated his CEO position and continues serve as a Director, Chief Financial Officer (“CFO”) and Treasurer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000075/0001740797-23-000075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"vacated"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"e0af7bfe8d","claim":"Paul Averill resigned as Chief Operating Officer at AVAI BIO, INC..","evidence_excerpt":"Effective November 3, 2023, Paul Averill resigned as Chief Operating Officer (“COO”) of the Company, so that he may fully devote his efforts to his other business.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740797/000174079723000075/0001740797-23-000075-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}